Connect Biopharma Unveils Promising Data for Rademikibart in Asthma and COPD Phase 2 Studies, Topline Results Expected 1H26

Reuters

2025/06/13

Connect Biopharma Unveils Promising Data for Rademikibart in Asthma and COPD Phase 2 Studies, Topline Results Expected 1H26

SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has announced the presentation of clinical data supporting their investigational drug, rademikibart, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress. The data, which demonstrates rademikibart's potential to significantly improve lung function and reduce annualized exacerbations in patients with eosinophilic-driven type 2 asthma, will be available from June 13-16, 2025, in Glasgow, United Kingdom, and virtually. These findings support ongoing Phase 2 acute exacerbation studies in asthma and chronic obstructive pulmonary disease (COPD), with topline data expected in the first half of 2026. Presentations are accessible on Connect Biopharma's website under the presentations and publications section.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467963-en) on June 13, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2543687843"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543687843\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543687843?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543687843","market":"nz","top_or_hot":-1,"title":"Connect Biopharma Unveils Promising Data for Rademikibart in Asthma and COPD Phase 2 Studies, Topline Results Expected 1H26","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Connect Biopharma Unveils Promising Data for Rademikibart in Asthma and COPD Phase 2 Studies, Topline Results Expected 1H26\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has announced the presentation of clinical data supporting their investigational drug, rademikibart, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress. The data, which demonstrates rademikibart's potential to significantly improve lung function and reduce annualized exacerbations in patients with eosinophilic-driven type 2 asthma, will be available from June 13-16, 2025, in Glasgow, United Kingdom, and virtually. These findings support ongoing Phase 2 acute exacerbation studies in asthma and chronic obstructive pulmonary disease (COPD), with topline data expected in the first half of 2026. Presentations are accessible on Connect Biopharma's website under the presentations and publications section.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467963-en) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Connect Biopharma Unveils Promising Data for Rademikibart in Asthma and COPD Phase 2 Studies, Topline Results Expected 1H26</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConnect Biopharma Unveils Promising Data for Rademikibart in Asthma and COPD Phase 2 Studies, Topline Results Expected 1H26\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-13 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Connect Biopharma Unveils Promising Data for Rademikibart in Asthma and COPD Phase 2 Studies, Topline Results Expected 1H26\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has announced the presentation of clinical data supporting their investigational drug, rademikibart, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress. The data, which demonstrates rademikibart's potential to significantly improve lung function and reduce annualized exacerbations in patients with eosinophilic-driven type 2 asthma, will be available from June 13-16, 2025, in Glasgow, United Kingdom, and virtually. These findings support ongoing Phase 2 acute exacerbation studies in asthma and chronic obstructive pulmonary disease (COPD), with topline data expected in the first half of 2026. Presentations are accessible on Connect Biopharma's website under the presentations and publications section.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467963-en) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和數據","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL2XcTqR:1","article_id":"2543687843","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543687843","pubTimestamp":1749819628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SAN DIEGO, June 13, 2025  -- Connect Biopharma Holdings Limited , a clinical-stage biopharmaceutical company, has announced the presentation of clinical data supporting their investigational drug, rademikibart, at the European Academy of Allergy and Clinical Immunology  2025 Annual Congress. The data, which demonstrates rademikibart's potential to significantly improve lung function and reduce annualized exacerbations in patients with eosinophilic-driven type 2 asthma, will be available from June 13-16, 2025, in Glasgow, United Kingdom, and virtually. These findings support ongoing Phase 2 acute exacerbation studies in asthma and chronic obstructive pulmonary disease , with topline data expected in the first half of 2026. Presentations are accessible on Connect Biopharma's website under the presentations and publications section.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inf","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","CNTB":"康乃德生物医药","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Connect Biopharma公布了Rademikibart在哮喘和COPD 2期研究中的有希望的数据，预计1H26的主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTB":0.9,"NDAQ":0.9},"content_text":"Connect Biopharma Unveils Promising Data for Rademikibart in Asthma and COPD Phase 2 Studies, Topline Results Expected 1H26\n    \n\n        SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has announced the presentation of clinical data supporting their investigational drug, rademikibart, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress. The data, which demonstrates rademikibart's potential to significantly improve lung function and reduce annualized exacerbations in patients with eosinophilic-driven type 2 asthma, will be available from June 13-16, 2025, in Glasgow, United Kingdom, and virtually. These findings support ongoing Phase 2 acute exacerbation studies in asthma and chronic obstructive pulmonary disease (COPD), with topline data expected in the first half of 2026. Presentations are accessible on Connect Biopharma's website under the presentations and publications section.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467963-en) on June 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}